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Purpose: The aim of this study was to formulate and evaluate microencapsulated controlled 
release preparations of a highly water-soluble drug, stavudine, using Copolymers synthesized 
from acrylic and methacrylic acid esters (Eudragit RS 100 and RL 100) as the retardant 
material. .  
Methods: Microspheres were prepared by solvent evaporation method using an acetone / 
liquid paraffin system. Magnesium stearate was used as the droplet stabilizer and n-hexane 
was added to harden the microspheres. The prepared microspheres were characterized for 
their micromeritic properties and drug loading, as well by fourier transform infrared 
spectroscopy (FTIR), differential scanning calorimetry, x-ray powder diffractometry and 
scanning electron microscopy. The in vitro release studies were performed in pH 6.8, 
phosphate buffer.  
Results: The prepared microspheres were white, free flowing and spherical in shape. The 
drug-loaded microspheres showed 67-91% of entrapment and release was extended upto 6 
to 8 h. The infrared spectra and differential scanning calorimetry thermographs showed stable 
character of stavudine in the drug-loaded microspheres and revealed the absence of drug-
polymer interactions. X-ray diffraction patterns showed that there was decrease in crystallinity 
of the drug. Scanning electron microscopy study revealed that the microspheres were 
spherical and porous in nature.  
Conclusion: The best-fit release kinetics was achieved with Higuchi plot followed by zero 
order and First order. The release of stavudine was influenced by the drug to polymer ratio 
and particle size & was found to be diffusion controlled.  
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INTRODUCTION 
The population of patient with chronic disease or 
complications of other disease has recently been 
increasing. These situations necessitate taking 
drug for a long period and / or multiple medicines 
simultaneously, which can lead to increase in 
non-compliance. The problem would be worse 
for drugs with short biological half-life. One 
method to solve such problems is to find a 
dosage form capable of releasing the drug 
gradually. Microencapsulation has been used as 
one of the methods to deliver drugs in a 
controlled manner1. Stavudine (D4T, thymidine) 
is the FDA-approved drug for clinical use for the 
treatment of HIV infection, AIDS and AIDS-
related conditions either alone or in combination 
with other antiviral agents. Stavudine is typically 
administered orally as a capsule and an oral 
solution. The virustatic drug has a very short 
half-life (1.30 h). However patients receiving 
stavudine develop neuropathy and lactic 
acidosis. The side effects of stavudine are dose-
dependent and a reduction of the total 
administered dose reduces the severity of the 
toxicity2. Microencapsulated techniques have 
mostly been used for lipophilic drugs since 
stearate was used as a droplet stabilizer to 
prevent droplet coalescence in the oil medium 
and n-hexane was added as a non-solvent to the 
processing medium to solidify the 
microspheres5. The effect of various processing 
and formulation factors such as drug to polymer 
ratio, stirring speed and surfactant concentration 
on the mean particle size of microspheres was 
investigated. The prepared spherical 
microspheres were evaluated for micromeritic 
properties and drug content, and also by FTIR, 
DSC, X-RD, SEM as well as for in vitro drug 
release studies6. 
 
MATERIALS AND METHODS  
Materials 
Stavudine was obtained as a gift from Hetero 
Labs Ltd. (Hyderabad, India). Eudragit RS 100 
and RL 100 was obtained from Röhm Pharma, 
GmbH, Darmstadt, Germany. All other reagents 
and solvents used were of pharmaceutical or 
analytical grade.  
Methods 
Stavudine microspheres were prepared 
by solvent evaporation techniques. Different 
amounts of Eudragit RS or Eudragit RS: RL 
combination was dissolved in 25 ml acetone 
  hydrophilic drugs showed low loading efficiency.  
The objective of the present investigation was to 
prepare the controlled release, microspheres of 
stavudine by improving biological half-life and 
entrapment efficiency. One method of ensuring 
high entrapment efficiency of water-soluble 
active ingredients is to use a hydrophobic 
processing medium into which the hydrophilic 
drug molecule is unlikely to migrate out3.  
        In this present study, stavudine 
microspheres were prepared by solvent 
evaporation technique using Eudragit RS 100 
and RL 100 as a matrix polymer4. Liquid paraffin 
and acetone system were used for the 
preparation of microspheres. Magnesium 
separately by using a magnetic stirrer (Remi 
Equipments, model 2MIH). Pure stavudine  (1 g 
previously dissolved in 10 ml methanol) and 
magnesium stearate [100 mg] were dispersed in 
the polymer solution. The resulting dispersion 
was then poured into 1000 ml beaker, containing 
the mixture of 270 ml liquid paraffin light and 30 
ml n-hexane, while stirring. A mechanical stirrer 
with a blade [4 cm diameter] (Remi Motors, 
Model No.RO-123R, Mumbai) was used. Stirring 
(at 500-700 rpm) was continued for 3 h, until 
acetone evaporated completely. After 
evaporation of acetone, the microsphere formed 
were filtered using Whatman no.1 filter paper. 
The residue was washed with 4-5 times in 50 ml 
 
Percent yield =  
the amount of microspheres obtained (g) 
        the theoretical amount (g) 
X 100 
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petroleum ether (400 C-600 C) each. 
Microspheres were dried at room temperature 
for 24 h. Formulations containing 1, 2 and 3 g of 
Eudragit RS only were assigned batch code as: 
FA1, FA2 and FA3 respectively and formulation 
with Eudragit RS: RL combinations as, 
0.8:0.2,1.8:0.2 and 2.8:0.2 g were assigned 
batch code: FA4, FA5 and FA6 respectively. All 
batches were prepared in triplicate. 
 Microspheres dried at room temperature 
were then weighed and the yield of 
microspheres preparation was calculated using 




Measurement of Micromeritic properties of 
microspheres  
 Measurement of Micromeritic properties 
of microspheres 
The flow properties of prepared microspheres 
were investigated by measuring the bulk density, 
tapped density, Carr’s index and packing factor. 
The bulk and tapped densities were measured in 
a 10 ml graduated measuring cylinder. The 
sample contained in the measuring cylinder was 
tapped mechanically by means of constant 
velocity rotating cam. The initial bulk volume and 
final tapped volume were noted from which, their 
respective densities were calculated. Each 
experiment was carried out in triplicate.  
 
Drug entrapment efficiency  
 About 50 mg of accurately weighed 
drug-loaded microspheres were added to 50 ml 
of phosphate buffer, pH 6.8. The resulting 
mixture was shaken in a mechanical shaker for 
24 h. The solution was filtered with a 0.45 µm 
pore size filter and 1 ml of this solution was 
appropriately diluted to 25 ml using phosphate 
buffer, pH 6.8, and analyzed 
spectophotometrically at 266 nm using Systronic 
2101 UV-Visible double beam Spectro-
photometer. 
 
Scanning Electron microscopy (SEM)  
 Scanning electron microscope (JEOL 
JSM -5200) was used to characterize the Shape 
and surface topography of the microspheres8. 
Prior to examination, samples were gold sputter-
coated to render them electrically conductive. 
 
Fourier Transform Infrared Spectroscopy 
(FTIR) 
 Drug-polymer interactions were studied 
by FTIR spectroscopy. The spectra were 
recorded for pure drug and drug-loaded 
microspheres using FTIR JASIO (Model No. 
410). Samples were prepared in KBr disks (2 mg 
sample in 200 mg KBr). The scanning range was 




Mean particle size  =  
Σ (Mean particle size of the fraction X weight fraction)  
        Σ Weight fraction 
 
Differential Scanning Calorimetry (DSC)  
The DSC analysis of pure drug and 
drug-loaded microspheres were carried out 
using a Diamond DSC (Perkin Elmer, USA) to 
evaluate any possible drug-polymer interaction9. 
The analysis was performed at a rate 5.000 C 
min -1 from 500 C to 2000  C temperature range 
under nitrogen flow of 25 ml min -1.  
 
X-ray powder Difftactometry [X-RD]  
 X-ray powder diffractometry was carried 
out to investigate the effect of 
microencapsulation process on crystallinility of 
drug. Powder X-RD patterns were recorded on 
Rigaku, Japan (Model-MenifleX) using Ni-
filtered, Cuk α radiation, a voltage of 30 kV and a 
current of 25 mA. The scanning rate employed 
was 20 min -1, over the 40 to 400 diffraction angle 
(2θ) range. The X-RD patterns of drug powder 
and drug-loaded microspheres were recorded.  
Drug release studies  
 The in vitro release studies of drug-
loaded microspheres were carried out at 370    C 
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and 100 rpm using phosphate buffer pH 6.8 (500 
ml) in a USP dissolution apparatus (LABINDIA, 
DISSO-2000, Mumbai, India) under sink 
conditions. Accurately weighed samples of 
microspheres (containing approx. 50 mg of drug, 
size fraction 250 µm) were added to dissolution 
medium and at preset time intervals 2 ml 
aliquots were withdrawn and replaced by an 
equal volume of fresh dissolution medium. After 
suitable dilution, the samples were analyzed 
spectophotometrically at 266 nm. The 
concentration of stavudine in test samples was 
corrected and calculated using a regression 
equation of the calibration curve.    
 
Release Kinetics  
 Data obtained from in vitro release 
studies were fitted to various kinetics equations10 
to find out the mechanism of drug release from 
microspheres. The kinetics models used were 
zero order, first order, and Higuchi models. The 
rate constants were also calculated for the 
respective models.  
RESULTS & DISCUSSION 
Effect of various processing and formulation 





It was observed that when the speed of stirrer 
was below 500 rpm, there was no formation of 
spherical microspheres. This could be due 
inadequate agitation to disperse the inner phase 
in the total mass. Therefore, particles were found 
to settle at the bottom of vessel. At stirrer speeds 
of 700-1000 rpm, the resulting high turbulence, 
caused frothing and adhesion to the container 
wall. Therefore, the mean particle size of 
microshperes decreased. The desired spherical 
microspheres were obtained at stirring speeds of 
500-700 rpm. When 50 mg magnesium stearate 
was incorporated, microspheres were not formed 
because the low magnesium content failed to 
prevent droplet coalescence in the oil medium; 
as a result mean particle size was increased. 
The mean particle size decreased with 
increasing amount of magnesium stearate (150 
mg). This is probably a consequence of 
stabilization of the oil droplets with magnesium 
stearate. Spherical microspheres were formed 
when the magnesium stearate content was 
maintained at 100 mg. When the drug: polymer 
ratio was 1: 1, there was formation of 
microspheres with small and irregular size, and 
as the polymer concentration was increased, 
solution viscosity also increased, resulting in 
large particles. Thus, mean particle size also 
increased. 
 
Flow properties of Microspheres  
        The flow properties are expressed in terms 
of Carr’s Index (see Table 1.). The Carr’s index 
for all formulations was less than 20, which 
indicates excellent flow compared to the original 
drug crystals. Also the microspheres were found 
to exhibit higher packing properties than the 
original drug crystals. The improvement in flow 
properties suggests that the microspheres can 




Fig. 1. SEM photographs of Eudragit RS
microspheres, before and after dissolution (A and C),
Eudragit RS: RL microspheres before and after
dissolution (B and D), cross-section of RS: RL
microsphere (E). 
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SEM study shows that particles were 
spherical. The surface of the drug-loaded 
microspheres manifested the presence of drug 
particles (see Fig. 1). The spherical nature and 
size of the microspheres did not change after the 
dissolution tests, but the number of pores 
increased. When a cross section of the 
microspheres were viewed it showed a spongy 
appearance. 
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Wave number (Cm-1) 
Fig. 2. FTIR Spectra of pure Stavudine (A), Eudragits RS 
loaded microspheres (B), Eudragit RS: RL  loaded 
Microspheres (C), Eudragit RS  blank Microsphered (D), 
Eudragit RS : RL blank Microspheres (E). 
 
Fourier Infrared Spectroscopy (FTIR)  
As shown in Fig. 2, there was no 
significant difference in the IR spectra of pure 
stavudine and drug-loaded microspheres (Both 
Eudragit RS and RS: RL loaded microspheres). 
The characteristic OH stretching, NH stretching 
of secondary amine, C-H stretching and C=O 
stretching of pure drug was unchanged in case 
of microspheres.  The results suggest drug 
stability during the encapsulation process. This 
was further supported by the DSC results that 
follow.  
 
Differential Scanning Calorimetry (DSC) 
The drug may have been dispersed in 
crystalline or amorphous form or dissolved in the 
polymeric matrix during formation of the of 
microspheres. Any abrupt or drastic change in 
the thermal behavior of either the drug or 
polymer may indicate a possible drug-polymer 
interaction11, 12. The thermo-gram of pure 
stavudine shows an endotherm at 1660 C., which 
correspond to its melting point (1610 C to 1670 
C). This endotherm was also observed for 
Eudragit RS100 microspheres at 1600 C but it 
was less sharp and this suggests that there is a 
significant reduction in drug crystallinity in the 
polymer matrix. 
Table 1. Physical characteristics of the microspheres. 
 Batch 
Code 




Carr’s Index Packing 
Factor 
Stavudine *** *** *** 27.62 ± 0.615 1.37 ± .015 
FA1 83 ± 6.30 466 ± 17.34 91.71 ± 1.46 8.87 ± 2.30 1.06 ± 0.023 
FA2 87 ± 3.90 534 ± 21.99 87.35 ± 1.59 10.45 ± 4.39 1.12 ± 0.083 
FA3 93.43 ± 1.87 600 ± 30.61 80.67 ± 1.34 13.59 ± 4.57 1.19 ± 0.047 
FA4 82.12 ± 5.77 463 ± 12.66 86.33 ± 0.77 6.74 ± 1.91 1.06 ± 0.023 
FA5 90.93 ± 1.68 545 ± 15 79.42 ± 1.10 8.49 ± 2.78 1.07 ± 0.037 
FA6 91.42 ± 3.78 609 ± 22.69 67.92 ± 1.60 9.55 ± 2.06 1.1 ± 0.026 
Note: *** the particular test not carried out for stavudine. 
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X-ray Powder Diffractometry (X-RPD)  
The X-ray powder diffraction patterns of pure 
drug, RS and RS: RL microspheres containing 
stavudine reveals that the intensity of the peaks 
for the pure drug was sharp. But when it was 
incorporated into the polymer matrix, the drug 
peaks showed a loss of sharpness due 
probably decreased crystallinity of the drug. 
Eudragit RS only was slow, but when RL was 
used in combination with RS, stavudine release 
from micro spheres was faster that is: FA4 > 
FA1, FA5 >FA2 and FA6 >FA3  (see fig. 3). This is 
due to the fact that the amount of quaternary 
ammonium groups of Eudragit RS is lower than 
that of Eudragit RL, which renders Eudragit RS 
is less permeable. It was also found that as the 
proportion of Eudragit RS was increased 
relative to drug concentration, the release rate 
of stavudine was decreased due to slower rate 
of diffusion through the polymer matrix.  
 
Release Kinetics  
The release mechanism of stavudine from 
various formulations was determined by 
comparing their respective correlation co-
efficient (see Table 2.). It would appear that the 
mechanism of drug release from microspheres 
was diffusion-controlled. When the release rate 
constants of stavudine microspheres were 
compared, it was found to follow the following 
order: FA4 >FA1>FA5>FA6 >FA2 > FA3.
 
CONCLUSION 
Stavudine microspheres was prepared 
successfully using the solvent evaporation 
method. Polymer: drug ratio, stirring speed and 
the content of magnesium stearate influenced 
the sphericity of the microspheres. The yield 
and entrapment efficiency were high for all 
formulations. It was observed that with increase 
in polymer concentration, the mean particle size 
of the microspheres increased but increasing 
the stirring speed and magnesium stearate 
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Fig.3. Cumulative percent release of 
Stavudine (n=3) from different microspheres 
prepared with different drug: polymer ratio.   
Drug release behavior  
The pure stavudine showed a fast release as 
98 % was released within 7 min. When it was 
encapsulated, sustained release up to 8 h was 
observed. For FA3, It was found that the release 
rate of drug from size fractions of 355 and 250 
µm was faster than that of 500 µm. This is 
because the smaller the particle size the larger 
the surface area available for drug release. The 
drug release from formulation containing 
particle size of microspheres. The assessment 
of the release kinetics revealed that drug 
release from stavudine microspheres followed 
Higuchi Model. It was suggested that 
mechanism of drug release from microspheres 
was diffusion-controlled. Controlled release 
without initial peak level achieved with these 
formulations may reduce dose frequency and 
side effects as well as improve patient 
compliance.   
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